No evidence to suggest existing vaccines don't work on Omicron: Centre

There is no evidence to suggest that existing Covid vaccines do not work on the Omicron variant, Union Health Minister Mansukh Mandaviya said

Mansukh L Mandaviya
Union Health Minister Mansukh L Mandaviya (PTI Photo)
IANS New Delhi
2 min read Last Updated : Dec 22 2021 | 7:57 AM IST

There is no evidence to suggest that existing Covid vaccines do not work on the Omicron variant, Union Health Minister Mansukh Mandaviya said on Tuesday.

"While there is no evidence to suggest that existing vaccines do not work on Omicron, some of the mutations reported on spike gene may decrease the efficacy of existing vaccines," he told the Rajya Sabha in a written reply.

Responding to a question on whether the vaccines being administered in the country are effective to develop immunity against the Omicron variant, he informed the house that there is limited available data, and no peer-reviewed evidence, on vaccine efficacy or effectiveness to date for Omicron. However, vaccine protection is also by antibodies as well as by cellular immunity, which is expected to be relatively better preserved.

"Hence, vaccines are expected to still offer protection against severe disease and, vaccination with the available vaccines remains crucial," he emphasised.

The Union Health Ministry, in a statement on Tuesday morning, said that the number of cases of new Covid strain Omicron has crossed the 200 -mark in India. However, out of them them, 77 patients have recovered or migrated.

Meanwhile, it has asked all states and UTs to gear up against the Omicron variant as it is three times more transmissible than the Delta variant, and formulate a strategy that can ensure infection is contained at the local level itself before it spreads to other parts of the state.

--IANS

avr/vd

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :OmicronCoronavirus VaccineMansukh Lal Mandaviya

First Published: Dec 22 2021 | 7:57 AM IST

Next Story